ÂÜÀòÂÒÂ×

Agnieszka ‘AJ’ Jurecka, M.D., Ph.D. joined CoA Therapeutics in August 2020 as VP, Clinical Development. Prior to joining CoA Therapeutics, AJ was Senior Medical Director, Global Clinical Development at Ultragenyx Pharmaceutical. While at Ultragenyx, AJ was responsible for clinical studies designed to address rare and ultrarare diseases, including mucopolysaccharidosis type VII (Mepsevii®) and long-chain fatty acid oxidation disorders (Dojolvi®). Her prior experience includes positions of increasing responsibility across medical affairs and clinical development at Aegerion, Shire, Synageva and BioMarin focusing on a variety of rare genetic diseases including homozygous familial hypercholesterolemia and numerous lysosomal storage diseases. During her career, AJ made significant contributions to several rare disease products such as Juxtapid®, Elaprase®, Kanuma® and Naglazyme®. Additionally, she has published more than 50 peer-reviewed scientific articles on inborn errors of metabolism and serves as a reviewer for over 15 journals.

AJ holds an M.D. (magna cum laude) from Silesian Medical University, Zabrze and a Ph.D from the Children’s Memorial Health Institute in collaboration with Postgraduate School of Molecular Medicine, Medical University of Warsaw, Poland and Purine Research Lab, Guy’s Hospital, London, UK. Her PhD thesis focused on selective screening programs for inborn errors of purine and pyrimidine metabolism and her postdoctoral fellowship was dedicated to study of lysosomal storage disorders.